Literature DB >> 16757333

Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases.

Joseph Avruch1, Maria Praskova, Sara Ortiz-Vega, Matthew Liu, Xian-Feng Zhang.   

Abstract

The six human Nore1/RASSF genes encode a family of putative tumor suppressor proteins, each expressed as multiple mRNA splice variants. The predominant isoforms of these noncatalytic polypeptides are characterized by the presence in their carboxyterminal segments of a Ras-Association (RA) domain followed by a SARAH domain. The expression of the RASSF1A and Nore1A isoforms is extinguished selectively by gene loss and/or epigenetic mechanisms in a considerable fraction of epithelial cancers and cell lines derived therefrom, and reexpression usually suppresses the proliferation and tumorigenicity of these cells. RASSF1A/Nore1A can cause cell cycle delay in G1 and/or M and may promote apoptosis. The founding member, Nore1A, binds preferentially through its RA domain to the GTP-charged forms of Ras, Rap-1, and several other Ras subfamily GTPases with high affinity. By contrast, RASSF1, despite an RA domain 50% identical to Nore1, exhibits relatively low affinity for Ras-like GTPases but may associate with Ras-GTP indirectly. Each of the RASSF polypeptides, including the C. elegans ortholog encoded by T24F1.3, binds to the Ste20-related protein kinases MST1 and MST2 through the SARAH domains of each partner. The recombinant MST1/2 kinases, spontaneous dimers, autoactivate in vitro through an intradimer transphosphorylation of the activation loop, and the Nore1/RASSF1 polypeptides inhibit this process. Recombinant MST1 is strongly activated in vivo by recruitment to the membrane; the recombinant MST1 that is bound to RasG12V through Nore1A is activated; however, the bulk of MST1 is not. Endogenous complexes of MST1 with both Nore1A and RASSF1A are detectable, and Nore1A/MST1 can associate with endogenous Ras in response to serum addition. Nevertheless, the physiological functions of the Nore1/RASSF polypeptides in mammalian cells, as well as the role of the MST1/2 kinases in their growth-suppressive actions, remain to be established. The Drosophila MST1/2 ortholog hippo is a negative regulator of cell cycle progression and is necessary for developmental apoptosis. Overexpression of mammalian MST1 or MST2 promotes apoptosis, as does overexpression of mutant active Ki-Ras. Interference with the ability of endogenous MST1/2 to associate with the Nore1/RASSF polypeptides inhibits Ras-induced apoptosis. At present, however, the relevance of Ki-Ras-induced apoptosis to the physiological functions of c-Ras and to the growth-regulating actions of spontaneously occurring oncogenic Ras mutants is not known.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757333     DOI: 10.1016/S0076-6879(05)07025-4

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  33 in total

1.  RASSF7 negatively regulates pro-apoptotic JNK signaling by inhibiting the activity of phosphorylated-MKK7.

Authors:  S Takahashi; A Ebihara; H Kajiho; K Kontani; H Nishina; T Katada
Journal:  Cell Death Differ       Date:  2010-11-19       Impact factor: 15.828

2.  Biochemical analysis of MST1 kinase: elucidation of a C-terminal regulatory region.

Authors:  Ruchi Anand; Ah-Young Kim; Michael Brent; Ronen Marmorstein
Journal:  Biochemistry       Date:  2008-06-24       Impact factor: 3.162

3.  Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.

Authors:  Bin Zhao; Li Li; Qing Lu; Lloyd H Wang; Chen-Ying Liu; Qunying Lei; Kun-Liang Guan
Journal:  Genes Dev       Date:  2011-01-01       Impact factor: 11.361

4.  Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation.

Authors:  Geoffrey K Kilili; John M Kyriakis
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

5.  The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2.

Authors:  Cai Guo; Xiaoying Zhang; Gerd P Pfeifer
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

6.  RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.

Authors:  Jessica J Mezzanotte; Victoria Hill; M Lee Schmidt; Thoraia Shinawi; Stella Tommasi; Dietmar Krex; Gabriele Schackert; Gerd P Pfeifer; Farida Latif; Geoffrey J Clark
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

7.  The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics.

Authors:  David Romano; Helene Maccario; Carolanne Doherty; Niall P Quinn; Walter Kolch; David Matallanas
Journal:  Mol Cell Biol       Date:  2013-03-04       Impact factor: 4.272

Review 8.  Cdc20: a potential novel therapeutic target for cancer treatment.

Authors:  Zhiwei Wang; Lixin Wan; Jiateng Zhong; Hiroyuki Inuzuka; Pengda Liu; Fazlul H Sarkar; Wenyi Wei
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis.

Authors:  Victoria Sherwood; Ria Manbodh; Carol Sheppard; Andrew D Chalmers
Journal:  Mol Biol Cell       Date:  2008-02-13       Impact factor: 4.138

10.  Comparative analysis of interactions of RASSF1-10.

Authors:  Jia Jia Chan; Delphine Flatters; Fernando Rodrigues-Lima; Jun Yan; Konstantinos Thalassinos; Matilda Katan
Journal:  Adv Biol Regul       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.